Recent news on Leustatin

Increased Risk of Second Malignancies in Hairy Cell Leukemia  -  Feb 15, 2007
Cancer Consultants (press release),Patients are usually treated initially with Leustatin® (2-CdA, cladribine) which results in reported relapse-free survivals of 70-80% at 4-5 years.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional